Objective To investigate the clinical epidemiological characteristics of gastric carcinoma detected by endoscopy in Gansu province.Methods Data of patients with gastric carcinoma,which was detected by endoscopy and confirmed pathologically from January 1977 to December 2006 in 163 hospitals of Gansu province,were reviewed.The endoscopic findings,clinical manifestations and epidemiological features were retrospectively analyzed.Results A total of 34,116 patients were diagnosed as gastric carcinoma with the overall screening rate as 5.30%,which was decreasing in the recent years.The rate of cardiac and noncardiac cancer was 18.5%and 81.5%,respectively,and the rate of cardiac cancer raised from 16.1%to 20.0%in the last decade.The tumor was most likely detected in antrum(38.63%).The male/female ratio of gastric cancer is 3.56:1.The screening rate of gastric carcinoma was the highest in Wuwei district (8.19%).The poorly differentiated adenocarcinoma accounted for 49.64%in all patients.Conclusion Gastric carcinoma occurs most frequently in Wuwei district of Gansu province and was mostly detected in gastric antrum.The most common pathological type is poorly differentiated adenocarcinoma.In the past three decades,the detection rate of gastric cancer is decreasing,SO is that of cardiac cancer,and that of the early gastric cancer is relatively low.

Immunotherapy mainly uses the effector units of the body's immune system to overcome the immune escape or adaptive immune resistance of tumors, accurately identify and remove tumor cells, and normalize or enhance the function of the immune system, which mainly includes cytokine therapy, immune checkpoint inhibition therapy, adoptive cell immunotherapy, tumor vaccine and antibody targeted therapy. The immune characteristics of nasopharyngeal carcinoma make the patients potentially suitable for immunotherapy or combined therapy with radiotherapy and chemotherapy. In recent years, PD-1 inhibitors alone and in combination with chemotherapy have shown good anti-tumor activity and safety in the treatment of recurrent/metastatic nasopharyngeal carcinoma. The incorporation of immune checkpoint inhibitors into the treatment paradigms of nasopharyngeal carcinoma has become a clinical research hot spot.